ReviewCurrent topics in medicinal chemistry2025
Guchang Zhixie Pill: A Comprehensive Review of the Clinical Applications, Toxicological Profile, and Quality Markers.
Review in Current topics in medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis study systematically reviews the clinical applications, toxicological profile, and quality markers of Guchang Zhixie Pill, offering a reference for its rational clinical use, as well as its quality and safety assessment.
methodsRelevant literature on the historical development, clinical applications, toxicology, and molecular characteristics of Guchang Zhixie Pill was retrieved from CNKI (https://www. cnki.net/), VIP (https://www.cqvip.com/), Sci-Hub (https://sci-hub.hkvisa.net/), TCMSP (https://old.tcmsp-e.com/tcmsp.php), Google Scholar (https://scholar.google.cz/schhp?hl=zh-CN), and PubMed (https://pubmed.ncbi.nlm.nih.gov/). Quality markers were predicted and analyzed based on established criteria to provide a scientific basis for ensuring clinical safety and efficacy.
resultsFormulated based on Wumei Pill, Guchang Zhixie Pill is widely used in the treatment of ulcerative colitis and irritable bowel syndrome. Quality marker prediction and analysis, conducted in accordance with the "five principles" of quality marker identification, indicated that ursolic acid, oleanolic acid, chlorogenic acid, neochlorogenic acid, citric acid, 5-hydroxymethylfurfural, coptisine, berberine hydrochloride, (+)-magnoflorine, 6-shogaol, 10-gingerol, dehydrocostus lactone, papaverine, noscapine, palmatine, and corydaline serve as potential Q-markers for this formulation.
conclusionAs a classical prescription for intestinal astringency and antidiarrheal therapy, ensuring its rational clinical application is essential. The identification of 16 quality markers provides a scientific reference for quality control in future research.
Indexed as
Identifiers
40129141What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.